
Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.

Your AI-Trained Oncology Knowledge Connection!

Christina Poh, MD, is an assistant professor at the University of Washington, Fred Hutchinson Cancer Center.

Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.

Christina Poh, MD, discusses the promising data supporting the chemotherapy-free combination of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Published: September 4th 2025 | Updated: